These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29212165)

  • 1. Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.
    Gleeson FC; Voss JS; Kipp BR; Kerr SE; Van Arnam JS; Mills JR; Marcou CA; Schneider AR; Tu ZJ; Henry MR; Levy MJ
    Oncotarget; 2017 Nov; 8(55):93464-93475. PubMed ID: 29212165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.
    Chou WC; Lin PH; Yeh YC; Shyr YM; Fang WL; Wang SE; Liu CY; Chang PM; Chen MH; Hung YP; Li CP; Chao Y; Chen MH
    Int J Biol Sci; 2016; 12(12):1523-1532. PubMed ID: 27994516
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
    Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
    Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability.
    Raj N; Shah R; Stadler Z; Mukherjee S; Chou J; Untch B; Li J; Kelly V; Saltz LB; Mandelker D; Ladanyi M; Berger MF; Klimstra DS; Reidy-Lagunes D; Osoba M
    JCO Precis Oncol; 2018; 2018():. PubMed ID: 30687805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.
    Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Graham RP; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
    Oncotarget; 2016 Aug; 7(34):54526-54536. PubMed ID: 27203738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms.
    Vandamme T; Beyens M; Boons G; Schepers A; Kamp K; Biermann K; Pauwels P; De Herder WW; Hofland LJ; Peeters M; Van Camp G; Op de Beeck K
    Endocr Relat Cancer; 2019 Jan; 26(1):1-12. PubMed ID: 30021865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
    Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
    Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profile and clinical features of patients with gliomas using a broad targeted next generation-sequencing panel.
    Romanidou O; Apostolou P; Kouvelakis K; Tsangaras K; Eliades A; Achilleos A; Loizides C; Lemesios C; Ioannides M; Kypri E; Koumbaris G; Papadopoulou K; Papathanasiou A; Rigakos G; Xanthakis I; Fostira F; Kotoula V; Fountzilas G; Patsalis PC
    Oncol Lett; 2023 Jan; 25(1):38. PubMed ID: 36589665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous Reports.
    Mowrey K; Northrup H; Rougeau P; Hashmi SS; Krueger DA; Ebrahimi-Fakhari D; Towbin AJ; Trout AT; Capal JK; Franz DN; Rodriguez-Buritica D
    Front Neurol; 2021; 12():627672. PubMed ID: 33897589
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular cytology genotyping of primary and metastatic GI stromal tumors by using a custom two-gene targeted next-generation sequencing panel with therapeutic intent.
    Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
    Gastrointest Endosc; 2016 Dec; 84(6):950-958.e3. PubMed ID: 27118626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.
    Wong HL; Yang KC; Shen Y; Zhao EY; Loree JM; Kennecke HF; Kalloger SE; Karasinska JM; Lim HJ; Mungall AJ; Feng X; Davies JM; Schrader K; Zhou C; Karsan A; Jones SJM; Laskin J; Marra MA; Schaeffer DF; Gorski SM; Renouf DJ
    Cold Spring Harb Mol Case Stud; 2018 Feb; 4(1):. PubMed ID: 29092957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.
    Weisbrod AB; Zhang L; Jain M; Barak S; Quezado MM; Kebebew E
    Horm Cancer; 2013 Jun; 4(3):165-75. PubMed ID: 23361940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and epigenetic alterations in pancreatic neuroendocrine tumors.
    Tirosh A; Kebebew E
    J Gastrointest Oncol; 2020 Jun; 11(3):567-577. PubMed ID: 32655936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.
    Schmitz D; Kazdal D; Allgäuer M; Trunk M; Vornhusen S; Nahm AM; Doll M; Weingärtner S; Endris V; Penzel R; Kirchner M; Brandt R; Neumann O; Sültmann H; Budczies J; Kienle P; Magdeburg R; Hetjens S; Schirmacher P; Bergmann F; Rudi J; Stenzinger A; Volckmar AL
    Genes Chromosomes Cancer; 2021 Jul; 60(7):489-497. PubMed ID: 33686791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation.
    Shen X; Wang X; Lu X; Zhao Y; Guan W
    Front Oncol; 2022; 12():967071. PubMed ID: 36248960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors.
    Chang TM; Shan YS; Chu PY; Jiang SS; Hung WC; Chen YL; Tu HC; Lin HY; Tsai HJ; Chen LT
    Oncotarget; 2017 Nov; 8(58):98068-98083. PubMed ID: 29228674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung cancer adrenal gland metastasis: Optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencing.
    Gleeson FC; Kipp BR; Levy MJ; Voss JS; Campion MB; Minot DM; Tu ZJ; Klee EW; Lazaridis KN; Kerr SE
    Cancer Cytopathol; 2014 Nov; 122(11):822-32. PubMed ID: 25045116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies.
    Arakelyan J; Zohrabyan D; Philip PA
    Cancer; 2021 Feb; 127(3):345-353. PubMed ID: 33270905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational landscape and potential therapeutic targets for sporadic pancreatic neuroendocrine tumors based on target next-generation sequencing.
    Zheng K; Liu T; Zhao J; Meng P; Bian Y; Ni C; Wang H; Pan Y; Wu S; Jiang H; Jin G
    Exp Ther Med; 2021 May; 21(5):415. PubMed ID: 33747156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.